---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268944"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:51:13.528611+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera reports Phase 1 data for STAT3 degrader KT-333: one PR in CTCL, no DLTs

## Summary
- 21 patients enrolled through dose level 5; 12 evaluable for disease assessment.
- One partial response in cutaneous T-cell lymphoma (CTCL) at DL2; stable disease in 3 solid tumor patients (DL3/4).
- No dose-limiting toxicities or serious adverse events; most AEs Grade 1/2 (constipation, fatigue, nausea, anemia).
- Dose-dependent, sustained STAT3 degradation in PBMCs at DL3+ at levels linked to preclinical anti-tumor activity.
- Updated data to be presented at ASH 2023 on December 10.

## SEC filing metadata
- accession: 0001193125-23-268944
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312523268944/0001193125-23-268944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312523268944/d590090d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268944
- JSON: https://secwatch.observer/filing/0001193125-23-268944.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.